Analysts Offer Insights on Healthcare Companies: Acelrx (NASDAQ: ACRX), Celldex (NASDAQ: CLDX) and Glaukos (NYSE: GKOS)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acelrx (NASDAQ: ACRX), Celldex (NASDAQ: CLDX) and Glaukos (NYSE: GKOS).

Acelrx (NASDAQ: ACRX)

In a report released yesterday, Boris Peaker from Cowen & Co. reiterated a Hold rating on Acelrx (NASDAQ: ACRX). The company’s shares opened today at $2.70, close to its 52-week low of $2.40.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 7.8% and a 40.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Corvus Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Acelrx has an analyst consensus of Strong Buy.

Celldex (NASDAQ: CLDX)

In a report released today, Joseph Pantginis from Roth Capital reiterated a Buy rating on Celldex (NASDAQ: CLDX), with a price target of $7. The company’s shares opened today at $3.15, close to its 52-week low of $2.96.

Pantginis wrote:

“We believe that the acquired preclinical and clinical programs have growth potential on their own, however they can also be combined with CLDX’s existing programs. 2017 should be data rich and we believe that investors should start accumulating positions.”

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -13.9% and a 30.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Currently, the analyst consensus on Celldex is Strong Buy and the average price target is $14, representing a 344.4% upside.

In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $9 price target.
Glaukos (NYSE: GKOS)

Roth Capital analyst Chris Lewis reiterated a Buy rating on Glaukos (NYSE: GKOS) today and set a price target of $41. The company’s shares opened today at $33.13.

Lewis noted:

“We see this as a significant upside driver to our estimates in 2017 and beyond as a 5% increase in U.S. ASPs implies ~$6.0MM revenue tailwind, per our model. Reiterate Buy .”

According to TipRanks.com, Lewis is a 4-star analyst with an average return of 1.9% and a 48.0% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Cogentix Medical Inc, Trinity Biotech Plc, and Natus Medical Inc.

Currently, the analyst consensus on Glaukos is Strong Buy and the average price target is $41.50, representing a 25.3% upside.

In a report issued on October 27, Wells Fargo also initiated coverage with a Buy rating on the stock.